Editorial
High-mobility group box 1 protein (HMGB1; also known as amphoterin) was initially identified more than 30 years ago as a non-chromosomal nuclear protein that maintains the nucleosome structure and regulates gene transcription.
1 HMGB1 is highly conserved among species, has over 98% identity among all mammals, and is ubiquitously expressed in almost all types of cells. HMGB1-deficient mice are viable but die shortly after birth due to hypoglycemia, suggesting that its nuclear functions are essential for survival. In 1999, Wang et al. 2 RAGE-signaling induces the activation of the nuclear factor-B (NF-B) pathway as well as signal transduction mediated by extracellular-regulated protein kinase1/2 (ERK1/2) and p38, which promote cytokine production and cell survival. In contrast, TLR2-and TLR4-signaling activate the NF-B pathway via a myeloid differentiation primary response protein 88 (MyD88)-dependent mechanism. The recent discovery of extracellular HMGB1 as a proinflammatory mediator has opened up avenues to help study the role of HMGB1 in inflammatory diseases.
A growing body of evidence suggests that inflammatory responses are involved in the pathophysiology of ischemic heart disease; therefore, it is postulated that HMGB1 acts as an inflammatory mediator in ischemic heart disease. Moreover increased levels of serum HMGB1 has been demonstrated in patients with acute coronary syndrome. 3 In the current issue of Cardiovascular Research, Kitahara et al. From the above discussion, it is clear that there is currently a disagreement regarding the role of HMGB1 in ischemic heart disease; the former two studies indicate that it is beneficial, while the latter suggests the contrary. The reason for this discrepancy remains unclear at present; however, we should consider the differences in the experimental conditions in these studies. First, in the former 2 studies, permanent ligation of the LAD artery was performed, i.e., permanent MI was induced; however, the latter study, the heart was reperfused after a 30-min ligation of the LAD artery.
There is a substantial difference between the pathophysiologies of permanent MI and ischemia-reperfusion injury. Reperfusion is accompanied by the release of an excessive amount of oxygen-derived free radicals that cause reperfusion injury. The inflammatory responses, including neutrophil and macrophage infiltration, are much more severe in reperfusion injury than in infarction, suggesting that ischemia-reperfusion injury could enhance inflammatory cell activity. Furthermore, HMGB1 stimulates the biological responses in endothelial cells and fibroblasts, [7] [8] [9] which participate in the healing process after MI. Indeed, Kitahara et al. 4 showed that angiogenesis after infarction was enhanced in MHC/HMGB1-Tg mice. Several investigations have revealed that HMGB1 functions as an angiogenic cytokine in endothelial cells. 7, 8 In particular, Chavakis et al. 9 have suggested that HMGB1 activates integrin-dependent recruitment of endothelial progenitor cells and contributes to angiogenesis in response to ischemia.
In addition, Rossini et al. 10 have reported that HMGB1 exerts paracrine effects on cardiac fibroblasts to stimulate the production of inflammatory cytokines and growth Although the 2 recent investigations by Kitahara et al. 4 and Andrassy et al. 6 significantly enhance our understanding regarding the role of HMGB1 in ischemic heart disease, there still remains a disagreement as to whether HMGB1 has beneficial or deleterious effects. Therefore, further investigations are necessary in order to understand the precise mechanism of HMGB1 action and its therapeutic potential in ischemic heart disease.
